WO1996009055A1 - New use of prostaglandins - Google Patents

New use of prostaglandins Download PDF

Info

Publication number
WO1996009055A1
WO1996009055A1 PCT/SE1995/001059 SE9501059W WO9609055A1 WO 1996009055 A1 WO1996009055 A1 WO 1996009055A1 SE 9501059 W SE9501059 W SE 9501059W WO 9609055 A1 WO9609055 A1 WO 9609055A1
Authority
WO
WIPO (PCT)
Prior art keywords
prostaglandin
prostaglandins
psoriasis
treatment
derivative
Prior art date
Application number
PCT/SE1995/001059
Other languages
French (fr)
Inventor
Johan Stjernschantz
Bahram Resul
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Priority to AU35817/95A priority Critical patent/AU705901B2/en
Priority to CA002200480A priority patent/CA2200480C/en
Priority to JP51080696A priority patent/JP4044611B2/en
Priority to EP95933000A priority patent/EP0778774B1/en
Priority to AT95933000T priority patent/ATE236638T1/en
Priority to US08/809,017 priority patent/US6031001A/en
Priority to DE69530303T priority patent/DE69530303T2/en
Publication of WO1996009055A1 publication Critical patent/WO1996009055A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • Psoriasis is a common dermatologic disorder affecting 1-2% of the population e.g. in Europe and United States. The disease usually debuts between the age of 10-40 years, but may become manifest at any age. Typically hyperkeratotic pink lesions covered by adherent silver- white scales can be found in patients suffering from psoriasis. The lesions have a characteristic shape and are well-demarcated. Not infrequently these lesions are localised to the elbows, knees, the gluteal regions and the scalp and it is generally believed that a cause of the psoriatic lesions is physical contact, pressure e.g. rubbing.
  • psoriasis The underlying mechanism of psoriasis is an increased proliferation of cells in the epidermis, primarily the keratinocytes. Thus, the epidermis becomes thick and hyperkeratotic, particularly superficially. The precise mechanism behind the stimulus of the cell proliferation is not known, but generally it is believed that trauma of the skin leads to an inflammatory reaction involving hyperproliferation of keratinocytes in the epidermis. There is a marked genetic disposition to develop psoriasis. Psoriasis may also become generalised over the whole body and psoriasis may cause arthritis, typically in the fingers. Psoriasis may fluctuate but complete and permanent remission is uncommon.
  • Psoriasis is usually treated with different medications. In simple cases, keratolytics, lubricants and topical corticosteroids are employed. Salicylic acid and anthralin are also used.
  • Another form of medical treatment is PUVA-treatment. PUVA-treatment is based on systemic or local administration of psoralens, e.g. methoxy-psoralen combined with irradiation of the skin with ultraviolet light (UVA) . This treatment modality is effective but may predispose to skin cancer.
  • Antimitotics, such as methotrexate have also been used in severe cases of psoriasis. Although there are presently many treatment modalities for psoriasis there is a definite need for more effective medications with less side-effects.
  • Prostaglandins are fatty acids usually derived from the precursors eicosatrienoic, eicosatetraenoic or eicosapentanoic acid through metabolic steps involving oxygenation.
  • Naturally occurring prostaglandins typically have the general structure
  • the prostaglandins accordingly carry a cyclopentane ring to which two carbon chains link, the upper usually being called the alpha chain and the lower usually being called the omega chain.
  • the prostaglandins are classified in subgroups A, B, C, D, E, F and J depending on the structure of the cyclopentane ring:
  • the alpha chain is a 7 carbon carboxy-terminated aliphatic chain whereas the omega chain is a 8 carbon methyl-terminated aliphatic chain.
  • subscripts of 1 to 3 are given.
  • the double bond is situated between carbons 13 and 14 in the omega chain, and it exhibits trans configuration in naturally occurring prostaglandins.
  • prostaglandins with subscript 2 e.g. PGA2 and PGJ2 an additional double bond in the cis configuration exists between carbons 5 and 6 in the alpha chain and finally in prostaglandins with subscript 3 a third double bond is situated between carbons 17 and 18 in the omega chain. This double bond also exhibits cis configuration in naturally occurring prostaglandins. All naturally occurring prostaglandins carry a hydroxyl group in carbon 15, which is essential for biologic activity.
  • prostaglandins for treatment of a great number of various diseases, including psoriasis, has been suggested, especially in patent publications, but no efficient prostaglandin derivative has to be best of our knowledge been presented for treatment of psoriasis.
  • Prostaglandins to be used according to the present invention are characterized by an ⁇ , ⁇ -unsaturated eye1opentenone and are in particular of the A and J type in which the cyclopentene ring has the basic structure.
  • the prostaglandins that have been utilized in the exemplification of the present invention are PGA2 and PGJ2• PGA2 is probably not a naturally occurring prostaglandin in man, but it is formed from PGE2 during acid extraction.
  • PGJ2 on the other hand is a well known metabolite of PGD2, which is a naturally occurring prostaglandin.
  • the molecular structures of PGA2 and PGJ2 are depicted in the figure given below.
  • Prostaglandin A2 ⁇ (5Z, 13E, 15S)-15- hydroxy-9-oxoprosta-5,10,13-trien-l-oic acid
  • prostaglandin J2 ⁇ (5Z,13E,15S)-15-hydroxy-ll-oxoprosta- 5,9,13-trien-l-oic acid) were purchased from Cayman Chemical Company (Ann Arbor, Michigan, USA) and used in acid form. Both compounds were dissolved in ethanol, and diluted to the final concentration directly in the cell growth medium.
  • Normal human epidermal keratinocytes (NHEK) derived from foreskin were purchased as secondary cultures (PromoCell, Heidelberg, Germany) and cultured in an optimized ready-to-use serum-free growth medium (KGM medium) (Promocell) at 37° C in 5% CO2, humidified air.
  • KGM medium serum-free growth medium
  • the growth medium is a modification of the MCDB 153 formulation and is supplemented with various concentrations of human epidermal growth factor, insulin, hydrocortisone, bovine pituitary extract and gentamicin/amphotericin B (proportions proprietary information of Promocell) .
  • PGA2 compound x
  • PGJ2 compound y
  • the results of the tests are depicted in Fig. 1 and 2. It can be seen that both PGA2 (compound x) and PGJ2 (compound y) markedly inhibited cell growth and reduced the total number of cells.
  • the growth inhibitory effects of the test compounds were noted microscopically after 48 hours, the first time point of observation.
  • PGA2 compound x
  • prostaglandins of the A and J type may be utilized for the treatment of psoriasis.
  • two prostaglandins namely PGA2 and PGJ2 were used, but analogues and derivatives of prostaglandins of the A and J type with the same fundamental mechanism of action may also be employed.
  • Analogues of PGA include e.g. 16,16- dimethyl-PGAi, ⁇ 7 -PGA ⁇ , ⁇ 7 -PGA2 and 16,16-dimethyl-PGA2.
  • PGJi Analogues or derivatives of PGJ include e.g. PGJi,
  • derivatives of the A and J type which are known from the literature and which are obvious candidates to be used for treatment according to the present invention.
  • One such group is the derivatives containing a ring substituted omega chain disclosed in PCT application SE89/00475.
  • alpha-chain modified prostaglandins may be employed, for instance derivatives containing alkyl substituents.
  • PGA and PGJ or their analogues may be modified to more lipophilic substances by esterification of different parts of the molecule, e.g. the carboxylic acid moiety.
  • esters that may be employed clinically because they penetrate better into the skin comprise alkyl esters with 1-10 carbon atoms and especially short alkyl esters e.g. methyl, ethyl, and isopropyl or cyclic esters such as benzyl.
  • the prostaglandin compounds and their esters or derivatives should be used in a suitable vehicle for topical application on the skin.
  • a suitable vehicle includes aqueous vehicles with or without solubilizers, stabilizers such as cyclodextrins, oils, ointments, micelle systems, nanoparticles and various slow release formulations.
  • Such vehicles may or may not contain preservatives depending on whether they are intended for single or multiple use.
  • Various preservatives that may be employed comprise e.g. benzalkonium chloride, chlorhexidine, thiomersal, parabenzoic acid and other compounds with satisfactory antimicrobial effect.
  • a formulation containing PGA2 or PGJ2 or derivatives of these prostaglandins is applied topically on the affected skin for different periods of time once or several times daily to treat the psoriatic lesions.
  • Such treatment may take only a few weeks or may go on for longer times depending on the clinical situation.
  • the recommended dose to be used depends on the particular prostaglandin and its physical-chemical characteristics but is usually in the range of from 0.01 to 100 ⁇ g per application. On an area of 1 dm 2 typically a dose of 0.1-10 ⁇ g per application is employed.
  • the medication can be instilled once or several times daily depending on the clinical situation, and the dosage form.
  • the invention also relates to the use of a a prostaglandin derivative as defined above for the preparation of a composition for treatment of psoriasis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composition comprising a therapeutically active and physiologically acceptable amount of prostaglandin A or prostaglandin J or a derivative of any one of these in a carrier, for treatment of psoriasis.

Description

New use of prostaglandins.
Psoriasis is a common dermatologic disorder affecting 1-2% of the population e.g. in Europe and United States. The disease usually debuts between the age of 10-40 years, but may become manifest at any age. Typically hyperkeratotic pink lesions covered by adherent silver- white scales can be found in patients suffering from psoriasis. The lesions have a characteristic shape and are well-demarcated. Not infrequently these lesions are localised to the elbows, knees, the gluteal regions and the scalp and it is generally believed that a cause of the psoriatic lesions is physical contact, pressure e.g. rubbing.
The underlying mechanism of psoriasis is an increased proliferation of cells in the epidermis, primarily the keratinocytes. Thus, the epidermis becomes thick and hyperkeratotic, particularly superficially. The precise mechanism behind the stimulus of the cell proliferation is not known, but generally it is believed that trauma of the skin leads to an inflammatory reaction involving hyperproliferation of keratinocytes in the epidermis. There is a marked genetic disposition to develop psoriasis. Psoriasis may also become generalised over the whole body and psoriasis may cause arthritis, typically in the fingers. Psoriasis may fluctuate but complete and permanent remission is uncommon.
Psoriasis is usually treated with different medications. In simple cases, keratolytics, lubricants and topical corticosteroids are employed. Salicylic acid and anthralin are also used. Another form of medical treatment is PUVA-treatment. PUVA-treatment is based on systemic or local administration of psoralens, e.g. methoxy-psoralen combined with irradiation of the skin with ultraviolet light (UVA) . This treatment modality is effective but may predispose to skin cancer. Antimitotics, such as methotrexate, have also been used in severe cases of psoriasis. Although there are presently many treatment modalities for psoriasis there is a definite need for more effective medications with less side-effects.
We have now unexpectedly found that certain prostaglandins may be useful for the treatment of psoriasis. Prostaglandins are fatty acids usually derived from the precursors eicosatrienoic, eicosatetraenoic or eicosapentanoic acid through metabolic steps involving oxygenation. Naturally occurring prostaglandins typically have the general structure
Figure imgf000004_0001
The prostaglandins accordingly carry a cyclopentane ring to which two carbon chains link, the upper usually being called the alpha chain and the lower usually being called the omega chain.
The prostaglandins are classified in subgroups A, B, C, D, E, F and J depending on the structure of the cyclopentane ring:
Figure imgf000004_0002
The alpha chain is a 7 carbon carboxy-terminated aliphatic chain whereas the omega chain is a 8 carbon methyl-terminated aliphatic chain. Depending on the number of double bonds in these chains subscripts of 1 to 3 are given. In prostaglandins with subscript 1, e.g. PGAi and PGJi, the double bond is situated between carbons 13 and 14 in the omega chain, and it exhibits trans configuration in naturally occurring prostaglandins. In prostaglandins with subscript 2, e.g. PGA2 and PGJ2 an additional double bond in the cis configuration exists between carbons 5 and 6 in the alpha chain and finally in prostaglandins with subscript 3 a third double bond is situated between carbons 17 and 18 in the omega chain. This double bond also exhibits cis configuration in naturally occurring prostaglandins. All naturally occurring prostaglandins carry a hydroxyl group in carbon 15, which is essential for biologic activity.
Therapeutic use of prostaglandins for treatment of a great number of various diseases, including psoriasis, has been suggested, especially in patent publications, but no efficient prostaglandin derivative has to be best of our knowledge been presented for treatment of psoriasis.
Prostaglandins to be used according to the present invention are characterized by an α,β-unsaturated eye1opentenone and are in particular of the A and J type in which the cyclopentene ring has the basic structure.
Figure imgf000005_0001
PGA PGJ
The prostaglandins that have been utilized in the exemplification of the present invention are PGA2 and PGJ2• PGA2 is probably not a naturally occurring prostaglandin in man, but it is formed from PGE2 during acid extraction. PGJ2 on the other hand is a well known metabolite of PGD2, which is a naturally occurring prostaglandin. The molecular structures of PGA2 and PGJ2 are depicted in the figure given below.
Figure imgf000006_0001
Figure imgf000006_0002
Exemplification of the invention
The invention is exemplified with the following non- limiting examples. Prostaglandin A2 { (5Z, 13E, 15S)-15- hydroxy-9-oxoprosta-5,10,13-trien-l-oic acid) and prostaglandin J2 { (5Z,13E,15S)-15-hydroxy-ll-oxoprosta- 5,9,13-trien-l-oic acid) were purchased from Cayman Chemical Company (Ann Arbor, Michigan, USA) and used in acid form. Both compounds were dissolved in ethanol, and diluted to the final concentration directly in the cell growth medium.
Normal human epidermal keratinocytes (NHEK) derived from foreskin were purchased as secondary cultures (PromoCell, Heidelberg, Germany) and cultured in an optimized ready-to-use serum-free growth medium (KGM medium) (Promocell) at 37° C in 5% CO2, humidified air. The growth medium is a modification of the MCDB 153 formulation and is supplemented with various concentrations of human epidermal growth factor, insulin, hydrocortisone, bovine pituitary extract and gentamicin/amphotericin B (proportions proprietary information of Promocell) .
For the experiments, cells at passage 3 were used. The effects of the prostaglandins were examined with a photometric cell proliferation assay after 5 days of continuous exposure. Cells were seeded into multiwell tissue culture plates containing KGM medium and quadruplicates of 50 nanomolar to 50 micromolar of the test compounds. KGM medium only, served as control. Every second day the culture medium was exchanged with fresh medium including the appropriate concentration of fresh prostaglandin to provide the cells with sufficient nutrients and to avoid problems that could arise from degradation of the test compound in the culture medium. After 5 days the cells were fixed in glutaraldehyde (1%) and stained by crystal violet (0.1 %) whereupon the stain was eluted by sodium lauryl sulphate (2.5%). The absorbanee of the colored solutions, shown to be linearly related to cell number, was monitored photometrically. The experiment was repeated once in its entirety.
The results of the tests are depicted in Fig. 1 and 2. It can be seen that both PGA2 (compound x) and PGJ2 (compound y) markedly inhibited cell growth and reduced the total number of cells. The growth inhibitory effects of the test compounds were noted microscopically after 48 hours, the first time point of observation. For PGA2 (compound x) , a decreased cell density but normal cell morphology, as compared to the control, was found in the wells containing 5 micromolar. At 25 and 50 micromolar most cells were still attached to the substratum but all cells were pyknotic, i. e. very small and irregular. For PGJ2 (compound y) , a reduction in the number of attached cells but normal cell morphology was found in the wells containing 0.5 micromolar. At 5 micromolar and higher con¬ centrations all cells appeared pyknotic. After 5 days the growth inhibitory effects of both compounds were even more pronounced (see Figs 1 and 2) . Both PGA2 (compound x) and PGJ2 (compound y) markedly suppressed growth and reduced the total number of cells in a dose-dependent manner. The highest concentrations tested reduced the cell numbers by 90 %. PGJ2 was the most potent compound and exerted a half-maximal growth inhibition at about 0.2 micromolar concentration. The corresponding value of PGA2 was about 1 uM. The control (compound z) which was the vehicle of the prostaglandin solutions had no effect on cell growth. Thus, both PGA2 and PGJ2 had marked inhibitory effect on the cultured human keratinocytes.
It is accordingly clearly indicated that prostaglandins of the A and J type may be utilized for the treatment of psoriasis. In the exemplification only two prostaglandins, namely PGA2 and PGJ2 were used, but analogues and derivatives of prostaglandins of the A and J type with the same fundamental mechanism of action may also be employed. Analogues of PGA include e.g. 16,16- dimethyl-PGAi, Δ7-PGAι, Δ7-PGA2 and 16,16-dimethyl-PGA2.
Analogues or derivatives of PGJ include e.g. PGJi,
Figure imgf000008_0001
There are also other types of derivatives of the A and J type which are known from the literature and which are obvious candidates to be used for treatment according to the present invention. One such group is the derivatives containing a ring substituted omega chain disclosed in PCT application SE89/00475. Also alpha-chain modified prostaglandins may be employed, for instance derivatives containing alkyl substituents.
PGA and PGJ or their analogues may be modified to more lipophilic substances by esterification of different parts of the molecule, e.g. the carboxylic acid moiety. Such esters that may be employed clinically because they penetrate better into the skin comprise alkyl esters with 1-10 carbon atoms and especially short alkyl esters e.g. methyl, ethyl, and isopropyl or cyclic esters such as benzyl.
The prostaglandin compounds and their esters or derivatives should be used in a suitable vehicle for topical application on the skin. A suitable vehicle includes aqueous vehicles with or without solubilizers, stabilizers such as cyclodextrins, oils, ointments, micelle systems, nanoparticles and various slow release formulations. Such vehicles may or may not contain preservatives depending on whether they are intended for single or multiple use. Various preservatives that may be employed comprise e.g. benzalkonium chloride, chlorhexidine, thiomersal, parabenzoic acid and other compounds with satisfactory antimicrobial effect.
Accordingly, in one aspect of the present invention a formulation containing PGA2 or PGJ2 or derivatives of these prostaglandins is applied topically on the affected skin for different periods of time once or several times daily to treat the psoriatic lesions. Such treatment may take only a few weeks or may go on for longer times depending on the clinical situation. The recommended dose to be used depends on the particular prostaglandin and its physical-chemical characteristics but is usually in the range of from 0.01 to 100 μg per application. On an area of 1 dm2 typically a dose of 0.1-10 μg per application is employed. The medication can be instilled once or several times daily depending on the clinical situation, and the dosage form. When the psoriatic lesion has regressed treatment may continue intermittently or may be terminated. The invention also relates to the use of a a prostaglandin derivative as defined above for the preparation of a composition for treatment of psoriasis.

Claims

Claims :
1. Composition comprising a therapeutically active and physiologically acceptable amount of prostaglandin A or prostaglandin J or a derivative thereof in a carrier, for treatment of psoriasis.
2. A composition according to claim 1 wherein the prostaglandin is PGA or a derivative thereof
3.. A composition according to claim 1 wherein the prostaglandin is PGJ or a derivative thereof.
4. A composition according to any one of claims 1 - 3 wherein the prostaglandin is an ester, especially the isopropyl ester.
5. A method for the treatment of psoriasis which comprises contacting the skin with a composition comprising an effective amount of a therapeutically active and physiologically acceptable prostaglandin of the A or J type in a carrier.
6. A method according to claim 5 wherein the prostaglandin is PGA or a derivative thereof.
7. A method according to claim 5 wherein the prostaglandin is PGJ or a derivative thereof.
8. A method according to any one of claims 5 to 7, wherein the prostaglandin is an ester, especially the isopropylester
9. Use of a therapeutically active and physiologically acceptable prostaglandin of the A or J type for preparation of a composition for treatment of psoriasis.
10. Use according to claim 9, wherein the prostaglandin is an ester, especially the isopropylester.
PCT/SE1995/001059 1994-09-21 1995-09-19 New use of prostaglandins WO1996009055A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU35817/95A AU705901B2 (en) 1994-09-21 1995-09-19 New use of prostaglandins
CA002200480A CA2200480C (en) 1994-09-21 1995-09-19 New use of prostaglandins
JP51080696A JP4044611B2 (en) 1994-09-21 1995-09-19 New use of prostaglandins
EP95933000A EP0778774B1 (en) 1994-09-21 1995-09-19 New use of prostaglandins
AT95933000T ATE236638T1 (en) 1994-09-21 1995-09-19 NEW USE OF PROSTAGLANDINS
US08/809,017 US6031001A (en) 1994-09-21 1995-09-19 Use of prostaglandins
DE69530303T DE69530303T2 (en) 1994-09-21 1995-09-19 NEW USE OF PROSTAGLANDINE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9403158-0 1994-09-21
SE9403158A SE9403158D0 (en) 1994-09-21 1994-09-21 New use of prostaglandins

Publications (1)

Publication Number Publication Date
WO1996009055A1 true WO1996009055A1 (en) 1996-03-28

Family

ID=20395309

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1995/001059 WO1996009055A1 (en) 1994-09-21 1995-09-19 New use of prostaglandins

Country Status (10)

Country Link
US (1) US6031001A (en)
EP (2) EP1310256B1 (en)
JP (1) JP4044611B2 (en)
AT (2) ATE330613T1 (en)
AU (1) AU705901B2 (en)
CA (1) CA2200480C (en)
DE (2) DE69535081T2 (en)
ES (2) ES2194055T3 (en)
SE (1) SE9403158D0 (en)
WO (1) WO1996009055A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773075A1 (en) * 1997-12-31 1999-07-02 Cird Galderma USE OF PPAR-GAMMA ACTIVATORS IN DERMATOLOGY
US5981586A (en) * 1997-05-23 1999-11-09 Pershadsingh; Harrihar A. Methods for treating proliferative and inflammatory skin diseases
WO2000050040A1 (en) * 1999-02-25 2000-08-31 Synphora Ab Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula
EP1390026A4 (en) * 2001-05-03 2006-02-22 Cornell Res Foundation Inc Treatment of hpv caused diseases
WO2006019353A1 (en) * 2004-08-17 2006-02-23 Synphora Ab Composition and method for the treatement of psoriasis

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702681D0 (en) * 1997-07-10 1997-07-10 Pharmacia & Upjohn Ab Method and composition for treatment of impotence
JP4834224B2 (en) 1999-03-05 2011-12-14 デューク ユニバーシティ C16 unsaturated FP-selective prostaglandin analogs
US6894175B1 (en) * 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
WO2003057162A2 (en) * 2002-01-04 2003-07-17 Combinatorx, Incorporated Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases
WO2003092617A2 (en) * 2002-05-03 2003-11-13 Combinatorx, Incorporated Combinations for the treatment of inflammatory skin disorders
US20040002514A1 (en) * 2002-06-14 2004-01-01 Alcon, Inc. Topical use of hydroxyeicosatetraenoic acid compounds to treat psoriasis
KR100760430B1 (en) * 2004-12-31 2007-10-04 한미약품 주식회사 Controlled release complex formulation for oral administration of medicine for diabetes and method for the preparation thereof
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US9328060B2 (en) 2013-10-18 2016-05-03 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460285A1 (en) * 1973-12-25 1975-07-03 Ono Pharmaceutical Co TRANS-DELTA HIGH 2-PROSTAGLAND COMPOUNDS, PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THESE
US4009282A (en) * 1973-12-17 1977-02-22 The Regents Of The University Of Michigan Treatment of proliferating skin diseases with prostaglandins
EP0097023A2 (en) * 1982-06-10 1983-12-28 Ono Pharmaceutical Co., Ltd. Prostaglandin D derivatives, process for their preparation and compositions containing them
EP0242580A2 (en) * 1986-03-13 1987-10-28 The Trustees Of Columbia University In The City Of New York Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
CZ277720B6 (en) * 1990-12-29 1993-03-17 Vysoka Skola Chem Tech Pharmaceutic gel containing natural prostaglandins for topic use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254145A (en) * 1978-08-16 1981-03-03 American Cyanamid Company Topical application of prostaglandin hypotensive agents
ES2317964T5 (en) * 1988-09-06 2015-02-20 Pfizer Health Ab Prostaglandin-F2alfa derivative for the treatment of glaucoma or ocular hypertension

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4009282A (en) * 1973-12-17 1977-02-22 The Regents Of The University Of Michigan Treatment of proliferating skin diseases with prostaglandins
DE2460285A1 (en) * 1973-12-25 1975-07-03 Ono Pharmaceutical Co TRANS-DELTA HIGH 2-PROSTAGLAND COMPOUNDS, PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THESE
EP0097023A2 (en) * 1982-06-10 1983-12-28 Ono Pharmaceutical Co., Ltd. Prostaglandin D derivatives, process for their preparation and compositions containing them
EP0242580A2 (en) * 1986-03-13 1987-10-28 The Trustees Of Columbia University In The City Of New York Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
CZ277720B6 (en) * 1990-12-29 1993-03-17 Vysoka Skola Chem Tech Pharmaceutic gel containing natural prostaglandins for topic use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 121, no. 8, 22 August 1994, Columbus, Ohio, US; abstract no. 91772J, page 610; *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981586A (en) * 1997-05-23 1999-11-09 Pershadsingh; Harrihar A. Methods for treating proliferative and inflammatory skin diseases
FR2773075A1 (en) * 1997-12-31 1999-07-02 Cird Galderma USE OF PPAR-GAMMA ACTIVATORS IN DERMATOLOGY
WO1999034783A1 (en) * 1997-12-31 1999-07-15 Galderma Research & Development, S.N.C. USE OF PPAR-η ACTIVATORS IN DERMATOLOGY
US6403656B1 (en) 1997-12-31 2002-06-11 Galderma Research & Development S.N.C Use of ppar-γ activators in dermatology
WO2000050040A1 (en) * 1999-02-25 2000-08-31 Synphora Ab Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula
US6495563B1 (en) 1999-02-25 2002-12-17 Synphora Ab Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula
AU767411B2 (en) * 1999-02-25 2003-11-06 Synphora Ab Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula
EP1390026A4 (en) * 2001-05-03 2006-02-22 Cornell Res Foundation Inc Treatment of hpv caused diseases
WO2006019353A1 (en) * 2004-08-17 2006-02-23 Synphora Ab Composition and method for the treatement of psoriasis

Also Published As

Publication number Publication date
EP1310256A2 (en) 2003-05-14
AU3581795A (en) 1996-04-09
AU705901B2 (en) 1999-06-03
CA2200480C (en) 2003-03-25
SE9403158D0 (en) 1994-09-21
DE69530303D1 (en) 2003-05-15
ATE330613T1 (en) 2006-07-15
DE69530303T2 (en) 2004-02-12
CA2200480A1 (en) 1996-03-28
DE69535081D1 (en) 2006-08-03
EP1310256B1 (en) 2006-06-21
EP1310256A3 (en) 2003-06-25
EP0778774A2 (en) 1997-06-18
EP0778774B1 (en) 2003-04-09
JP4044611B2 (en) 2008-02-06
ES2263853T3 (en) 2006-12-16
JPH10505861A (en) 1998-06-09
US6031001A (en) 2000-02-29
ES2194055T3 (en) 2003-11-16
ATE236638T1 (en) 2003-04-15
DE69535081T2 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
EP0778774B1 (en) New use of prostaglandins
US5770582A (en) Pharmaceutical compositions containing deoxyribonucleosides for wound healing
US4871752A (en) Use of aryloxycarboxylic acid derivatives against dermatological diseases
US5324746A (en) Method of treating damaged mucosal and epithelial tissues with misoprostol
US6589990B1 (en) Methods and compositions for misoprostol compound treatment of erectile dysfunction
US6399082B1 (en) Mixture of a diol and an alpha-hydroxy acid for the treatment of hyperkeratotic skin diseases
US5254538A (en) Method of treating periodontal disease
AU621368B2 (en) Pharmaceutical composition containing deoxyribonucleosides and/or deoxyribonucleotides for wound healing
Ramamurthy et al. Topically applied CMT-2 enhances wound healing in streptozotocin diabetic rat skin
Sanquer et al. Human Dermal Fibroblasts Modulates the Effects of Retinoids on Epidermal Growth
EP0782447B1 (en) Use of prostaglandins for the manufacture of a medicament for prevention and treatment of secondary cataract
EP0494995A1 (en) Cosmetic method of inhibiting the formation of a scar
US5994399A (en) Method of regenerating collagen-containing tissues with misoprostol
US6919320B1 (en) Pharmaceutical compositions containing deoxyribonucleosides for wound healing
Oprica et al. Overview of treatments for acne.
US20060041016A1 (en) Composition and method for the treatment of psoriasis
JP2003226644A (en) Remedy for stomatitis
MXPA00005078A (en) Use of a mixture of a diol and an alpha-hydroxy acid for the treatment of hyperkeratotic skin diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KE KG KP KR KZ LK LR LT LV MD MG MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 1995933000

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2200480

Country of ref document: CA

Ref country code: CA

Ref document number: 2200480

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 08809017

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1995933000

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1995933000

Country of ref document: EP